Cannabix Technologies Develops Beta 3.0 Marijuana Breathalyzer and Provides Update
July 31 2017 - 8:00AM
InvestorsHub NewsWire
7934 Government Road, Burnaby, B.C.,
V5A 2E2
Phone: (604) 551-7831
Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
The Cannabix Marijuana Breathalyzer is
being developed to give law enforcement and employers a tool to
enforce public safety
Vancouver, BC -- July 31, 2017 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF)
(the “Company or Cannabix”) developer of the Cannabix Marijuana
Breathalyzer for law enforcement and the workplace, is pleased to
announce that it has developed a “Beta 3.0” (Cannabix Marijuana
Breathalyzer) device based on its FAIMS- (field
asymmetric waveform ion mobility spectrometry)
technology with
major advances in the design and commercial capabilities of the
device. The Beta 3.0 will include a conventional rechargeable
battery, improved ion flow, the latest pulse driver chips to
improve resolution and sensitivity. The new design includes
improvements that will allow for dynamic testing and for easier
configurability that will be needed for more demanding test/user
environments.
The Beta 3.0 device will also include a
specialized flow-through heat exchanger technology that stabilizes
breath temperature in cold as well as humid temperature settings
and allows for breath testing in all temperature
conditions. The
new device includes improved dielectric barrier discharge
ionization source and high-voltage square wave generator which has
been given superior voltage shielding. The
Beta 3.0 device incorporates real time breath
analysis for concentrations of O2, CO2,
humidity, temperature and flow-rate which will allow for key
metrics for real-time detection of
delta-9-tetrahydrocannabinol (“THC”) in human
breath.
Testing update and Establishment of British
Columbia Testing Laboratory
Cannabix has been developing its
FAIMS based Cannabix Marijuana Breathalyzer for
the detection of THC through exhaled breath and continues testing
its devices in British Columbia and Florida for sensitivity and
consistency of results for Evidential Breath testing
purposes.
Recent testing with the Cannabix Marijuana
Breathalyzer Beta 2.0 prototype device with human subjects after
smoking THC cigarettes demonstrated the successful identification
of THC in relation to the subject’s background matrix in real-time.
(THC being the psychoactive component of marijuana). In
addition to THC, several
metabolites were identified in the
breath of the human subjects
including 11-hydroxy-delta-9-tetrahydrocannabinol and
delta-9-carboxy-tetrahydrocannabinol, the results
were confirmed by mass spectrometry after the
inhalation of cannabis.
The
Company has substantially increased its testing capabilities with
investment in a state-of-the art lab space in Vancouver, B.C.,
purchase of Thermo Scientific mass spectrometer and related
equipment. Cannabix has also added to its technical team with
the addition of Dr. David Hasman who is an expert in the field of
toxicology and forensic science as well the operation of mass
spectrometer based testing devices.
Furthermore, the Company is in
discussions to collaborate, using the Cannabix Marijuana
Breathalyzer, with a significant U.S. based institution with large
user group and enhanced testing environment.
About Cannabix Technologies Inc
Cannabix Technologies Inc. is a leader in
marijuana breathalyzer development for law enforcement and the
workplace. Cannabix has established breath testing technologies in
the pursuit of bringing durable, portable hand-held tools to market
to enhance detection of marijuana impaired driving offences on
roads at a time when marijuana is becoming legal in many global
jurisdictions. Cannabix is working to develop drug-testing devices
that will detect THC- the psychoactive component of marijuana that
causes intoxication- using breath samples. In particular, Cannabix
is focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects use days or even
weeks earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains
forward-looking information that involves various risks and
uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company’s plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (v) the ability of the Company to develop and market
its future product; and (vi) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2023 to Sep 2024